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Both deficiencies and excesses of iron represent major public health problems throughout the world. Understanding the cellular and organismal
processes controlling iron homeostasis is critical for identifying iron-related diseases and in advancing the clinical treatments for such disorders of
iron metabolism. Iron regulatory proteins (IRPs) 1 and 2 are key regulators of vertebrate iron metabolism. These RNA binding proteins post-
transcriptionally control the stability or translation of mRNAs encoding proteins involved in iron homeostasis thereby controlling the uptake,
utilization, storage or export of iron. Recent evidence provides insight into how IRPs selectively control the translation or stability of target
mRNAs, how IRP RNA binding activity is controlled by iron-dependent and iron-independent effectors, and the pathological consequences of
dysregulation of the IRP system.
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Protein kinase C1. Introduction
1.1. Necessity and toxicity of iron
Iron is considered a micronutrient because the adequate daily
intake is in the low milligram range [1]. Despite this relatively
low dietary requirement, iron deficiency is a major global health
problem due, in part, to the low abundance of iron in many foods
coupled with reduced bioavailability of non-heme iron, a com-
mon dietary iron source. Impairment of health caused by nutri-
tional iron deficiency affects more than 2 billion people
worldwide resulting in significant negative social and economic
impacts [2,3]. In fact, iron deficiency is listed by theWorldHealth
Organization as one of the top ten leading risk factors for
significant health impairment or death [4]. While most affected
individuals live in developing countries, even industrialized areas
such as the United States have significant numbers of affected
individuals [5]. The nutritional requirement for iron in vertebrates
arises because it is an essential component of proteins that⁎ Corresponding author. Tel.: +1 608 262 5830.
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doi:10.1016/j.bbamcr.2006.05.004perform redox or non-redox roles in many critical cellular
functions including respiration and cell division. In addition to
anemia, iron deficiency impairs muscle, immune and cognitive
function and can increase the incidence of low birthweight and
preterm delivery [6–11]. It is worth noting that iron deficiency
can impair health in the absence of anemia and a significant
fraction of the two billion individuals suffering pathological
consequences of iron deficiency fall into this category [12]. Given
the significant impact of iron deficiency on human health, there is
much interest in accurately quantifying its occurrence, reducing
its prevalence, as well as understanding how cells and tissues
respond to deficiencies or excesses of this critical nutrient
[2,3,13,14].
Dysregulation of iron metabolism associated with hemochro-
matosis and other iron overload disorders is also a significant
health concern [15–19]. Iron's toxicity arises due to iron-induced
formation of reactive oxygen species (ROS) that damage cellular
structures [20]. In hemochromatosis, iron overload damages the
liver, pancreas, heart and other tissues. Furthermore, iron overload
is causative of, or has been associated with the development of,
several neurodegenerative diseases including Parkinson's, Frie-
dreich's ataxia, Aceruloplasminemia, Pantothenate kinase
669M.L. Wallander et al. / Biochimica et Biophysica Acta 1763 (2006) 668–689deficiency and others [20–26]. The molecular basis for diseases
of iron overload includes improper control of fundamental
pathways of iron metabolism such as iron absorption or transport,
iron–sulfur protein biogenesis, iron storage, or, in an animal
model, the general control of iron metabolism by iron regulatory
protein 2 (IRP2), all of which can lead to degenerative processes
in specific tissues [27–31]. In order to maintain optimal health,
the concentration and distribution of iron must be tightly
controlled to provide enough to meet cellular requirements
while avoiding excessive levels that are toxic. Understanding the
tissue and cell-type specific processes underlying the control of
iron homeostasis remains a critical factor in identifying iron-
related diseases and in advancing the clinical treatments for such
disorders of iron metabolism [19].
2. Brief overview of whole body and cellular iron homeostasis
2.1. Dietary iron absorption
Multiple physiological processes are used to maintain iron
homeostasis in diverse organisms. These include the absorption,
use, storage and export of iron. In mammals, absorption of
dietary iron represents the only means to regulate body ironFig. 1. Control of mammalian iron homeostasis by the IRE/IRP regulatory network
encoded by IRE-containing mRNAs (red lettering). Tf-Fe3+ binds to Tf R on the ce
endosome causes the release of Fe3+ (red balls) from TF where it is reduced to Fe2+
DMT1 (divalent metal transporter 1). ApoTf/Tf R complex is then returned to the cell s
iron uptake is ubiquitous, but it is especially important in erythroid precursor cells wh
localized on the apical membrane of duodenal enterocytes where it transports Fe2+ red
of metalloreductases [300]. Iron taken up by the Tf R enters a cytosolic free iron pool t
iron in this pool and regulate the translation of 5′ IRE-containing mRNAs (H- and
ferroportin) or the stability of 3′ IRE-containing mRNAs (Tf R and possibly DMT1). e
in precursor erythroid cells. Mitochondrial aconitase is an enzyme in the tricarboxylic
stored in ferritin is exported by ferroportin. Ferroportin is expressed in duodenal ente
oxidation of iron possibly by the membrane bound protein hephaestin (HP) or the secontent [32–34]. Identification of the transporters and other
proteins functioning in the absorption of dietary non-heme and
heme iron has greatly enhanced the understanding of this
process that is central to the control of body iron content. Iron
can be absorbed as non-heme iron or heme iron with the latter
being more efficiently taken up [1]. A candidate for the long
sought intestinal transporter required for heme absorption was
recently identified [35,36]. Non-heme iron is absorbed through
the action of divalent metal transporter 1 (DMT1; also called
nRAMP2) and DCYTB, a ferrireductase, present at the apical
membrane in the proximal small intestine (Fig. 1) [37–39].
DMT1 is required for absorption of dietary non-heme iron after
birth but is not essential in all tissues [40]. Two isoforms of
DMT1 protein exist that differ at their C-terminus, have tissue
specific roles in iron absorption, and exhibit different
subcellular trafficking [41]. Mutation of DMT1 impairs iron
absorption and can cause microcytic anemia in animals and
humans [37,42–44]. Iron controls the abundance of DMT1
mRNA as well as the subcellular localization of the transporter
itself [37,38,45]. DCYTB was identified as a gene up-regulated
in duodenum in response to iron deficiency and other scenarios
causing enhanced iron absorption [39]. DCYTB is believed to
donate electrons for reduction of ferric iron to the ferrous state. A generic mammalian cell depicting the various roles of mammalian proteins
ll surface where the TF-Fe3+/Tf R complex is endocytosed. Acidification of the
(yellow balls) by the ferrireductase Steap3 before export from the endosome by
urfacewhere it dissociates and initiates another round of iron uptake. TF-mediated
ere it is the primary source of iron for utilization in heme synthesis. DMT1 is also
uced possibly by the membrane reductase DCYTB or a member of a Steap family
hought to consist of Fe2+ bound to small molecular weight molecules. IRPs sense
L-ferritin subunits, eALAS (erythroid aminolevulinate synthase), m-aconitase,
ALAS is a mitochondrial enzyme and the rate limiting enzyme in heme synthesis
acid cycle that requires a [4Fe–4S] cluster for activity. Iron that is not utilized or
rocytes, hepatocytes, placenta and macrophages. Export of iron is coupled to the
rum multicopper oxidase ceruloplasmin (CP).
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the essential role of DCYTB, at least in mice [46]. Once
internalized, iron traverses the intestinal mucosal cell but the
mechanism is not well understood, although it may involve
transcytosis [47]. Heme absorbed from the diet is presumably
degraded by heme oxygenase and the iron released enters the
intracellular non-heme iron pool. Export of iron into the
circulation requires the iron exporter ferroportin (FPN; also
called IREG1 and MTP1) [48] and a ferroxidase, to oxidize
iron so it can be bound by transferrin (TF). Ferroportin is
essential for iron export from enterocytes, macrophages and
hepatocytes [48]. Until recently the ferroxidase involved in
oxidizing iron exported by FPN has been presumed to be
hephaestin, a multicopper oxidase related to the long known
serum protein, ceruloplasmin [34]. Mutation of hephaestin, in
the sex-linked anemia mouse, causes microcytic anemia and
illustrates the importance of hephaestin in iron absorption
[34,49]. However, a recent study demonstrates a clear role for
ceruloplasmin in intestinal iron absorption under some
circumstances such as in response to acute phlebotomy [50].
In brain, a novel form of ceruloplasmin directly interacts with
FPN suggesting channeling of iron between the transporter
and ferroxidase; a similar situation exists in yeast [51,52]. An
analogous interaction between FPN and either ceruloplasmin
or hephaestin may occur in relation to the process of dietary
iron absorption. How apoTf directly acquires iron is not clear.
Major factors influencing the rate of intestinal iron absorption
are the size of body iron stores, the rate of erythropoiesis and
inflammation [32]. Dietary factors including the type of iron
(heme versus non-heme iron) and the presence of inhibitors or
enhancers of iron absorption also influence intestinal iron
absorption [1]. The recently discovered iron regulatory
hormone hepcidin has a critical role in controlling iron
absorption through its ability to bind to and control the cell
surface expression of FPN [53,54]. Hepcidin has a major role
in the control of body iron homeostasis in response to changes
in dietary iron intake and in pathological situations such as the
anemia of chronic disease.
2.2. Interorgan transport and cellular metabolism of iron
One or twomilligrams of iron is absorbed bymen andwomen,
respectively, every day. However, on a daily basis, themajority of
iron flux in the body (i.e. ∼25 mg), flows through a tightly
controlled cycle between the erythron and the reticuloendothelial
(RE) system [1,55]. In this process, senescent red cells are
engulfed by macrophages of the RE, such as liver Kupffer cells
[55]. Heme from the destroyed red cells is degraded and exported
through the action of ferroportin and a ferroxidase, presumably
ceruloplasmin, although recent evidence suggests another fer-
roxidasemay be involved [50]. The ferric iron so-formed binds to
serum apoTf forming holoTF. TF binds two iron atoms, in the
ferric oxidation state, with extremely high affinity. HoloTF can
then travel to the bone marrow and be used for formation of new
erythrocytes, which completes the red cell cycle.
Transferrin-mediated iron uptake represents the primary
means for uptake of non-heme iron by most cell types. HoloTFbinds to cell surface transferrin receptor 1 (TfR1) and the TfR1/
TF complex is internalized through receptor-mediated endocy-
tosis (Fig. 1) [56,57]. The process of iron release to the cytosol
requires endosomal acidification, reduction of iron by a recently
identified ferrireductase, Steap3 [58], and ferrous iron export to
the cytosol through the action of DMT1 [42]. Release of iron from
TF is stimulated by the interaction of TF with TfR1 (reviewed in
[56,57,59]). The complex of TfR1 and apoTF is returned to the
cell surface, completing the TF/TfR1 cycle (Fig. 1), and apoTF is
released to be re-charged with iron (Fig. 1). Iron delivered to the
cytosol can be used for metabolic utilization and formation of
essential iron-containing proteins in both the mitochondria and
cytosol (Fig. 1). Mitochondria have a particularly important role
in the formation of iron-containing proteins since the majority of
iron–sulfur (Fe–S) proteins are made in this organelle, cytosolic
Fe–S cluster formation depends on mitochondrial function, and
several critical steps in heme formation take place in the mit-
ochondrial matrix where 5-aminolevulinate synthase (ALAS) and
ferrochelatase are found [60–62]. In the cytosol, excess iron can
be stored in ferritin, a large roughly spherical molecule composed
of twenty-four subunits of two types, heavy- (H) or light-chain (L)
ferritin which can store several thousand iron atoms [63], or be
exported by FPN. A critical aspect of the maintenance of cellular
iron homeostasis is the control of the expression of genes enco-
ding proteins required for the uptake (TfR1, DMT1), utilization
(5-aminolevulinate synthase (ALAS) and erythroid ALAS
(eALAS)), storage (H- and L-ferritin) or export (FPN) of iron
[19]. In order to coordinate these processes, sensing of cellular
iron status is required if organisms are to use iron-containing
proteins in essential metabolic pathways while simultaneously
avoiding the deleterious consequences of iron overload. Iron
regulatory proteins (IRPs) are central components of a sensory
and regulatory system required for the maintenance of iron
homeostasis in vertebrates.
2.3. IRPs are key iron sensors in vertebrates
Since its discovery in 1937 [64] the intriguing properties of
ferritin have stimulated many insightful studies that have helped
elucidate the major mechanisms for sensing and controlling
cellular and organismal iron homeostasis in vertebrates. Initial
studies by Granick and others demonstrated that ferritin abun-
dance and synthesis were iron-responsive [65–67]. Munro and
colleagues, as well as others, made the critical observation that
mammalian cells contained a cytosolic iron sensor that controlled
ferritin synthesis [68–70]. In a seminal study,Munro's laboratory
then demonstrated that iron stimulated ferritin synthesis by
activating the translation of ferritinmRNAs [71]. The next critical
step in studies of ferritin expression involved the identification of
an evolutionarily conserved 28 nucleotide (nt) sequence, termed
the iron responsive element (IRE), which was present in the 5′
untranslated region (UTR) of both H- and L-ferritin mRNAs. The
IRE proved to be necessary and sufficient for iron-dependent
control of ferritin mRNA translation [72–74]. These observations
occurred concurrently with the discovery of cytosolic iron-regu-
lated RNA binding proteins, IRP1 and IRP2, which recognize the
IRE in a sequence and structure specific manner [75,76]. The first
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controlling mammalian ironmetabolism arose from a comparison
of the findings concerning ferritin regulation with the observa-
tions of Kühn and associates, who showed that TfR1 mRNA
stability was iron-regulated and that the regulatory element res-
ponsible was present in the 3′ UTR [77,78]. In this manner,
Harford and colleagues then established that IRE-dependent post-
transcriptional control was central to the regulation of cellular iron
metabolism in vertebrates [79,80].
Since the discovery of IREs in H- and L-ferritin and TfR1
mRNAs, IRE or IRE-like elements have been identified in at least
ten animal cell mRNAs (Fig. 2) (reviewed in [10,19]). These
include the mRNAs encoding proteins involved in heme for-
mation in erythroid cells (eALAS); iron uptake, DMT1; iron
export, FPN as well as two tricarboxylic acid cycle enzymes,
mitochondrial aconitase (m-acon) and the iron-protein subunit of
succinate dehydrogenase [81]. These studies have established the
central role of the IRE-IRP system in controlling ironmetabolism
in vertebrates and some invertebrates, and have served as impetus
for the discovery of other post-transcriptional regulatory net-
works with similar physiological roles in lower eukaryotes and
prokaryotes [82–86]. Putative IREs have been observed in three
novel mRNAs. Glycolyate oxidase (GOX) mRNAwas found to
contain a putative IRE in its 5′ UTR [87]. More recently a single
putative IRE was discovered in the 3′ UTR of myotonic
dystrophy kinase-related Cdc42-binding kinase α (MRCK α)
and in one splice variant of CDC14A mRNAs [88,301]. These
observations point towards an expanded role for IRP in cell
physiology. The presence of a putative IRE in MRCK α mRNA
suggests a role for IRPs in cytoskeletal dynamics, which may
possibly be related to endocytosis of TF, while the putative IRE in
CDC14A suggests new roles for iron in cell division. WhetherFig. 2. Cellular regulation of mammalian iron homeostasis by the IRPs. IRPs bind to
conditions, IRP1 and IRP2 bind with high affinity to 5′ IREs and to the five 3′ IRE
mRNAs and the stabilization of the Tf R mRNA. During high iron conditions, IRPs lo
mediating degradation of the Tf R mRNA. Increased iron levels result in the convers
increased iron and/or heme levels mediate IRP2 proteasomal degradation. WhetherIRPs have a physiological role in controllingGOX,CDC14A and
MRCK α expression remains to be elucidated.
2.4. IRPs control mRNA translation or stability
IRP1 and IRP2 are key cytosolic iron sensors in mammalian
cells. When cells are iron-deficient, IRPs bind IREs with high
affinity (KD ∼20–100 pM), inhibiting the translation of ferritin
and other mRNAs containing 5′ IREs while stabilizing mRNAs
containing 3′ IREs, such as TfR1 mRNA (Fig. 2). When cells
are iron-sufficient, IRPs lose their high affinity RNA binding
capacity and fail to bind to IREs. Consequently, ferritin synthesis
is activated while TfR1 mRNA is degraded. The post-trans-
criptional regulation of ferritin and TfR1 mRNAs by IRPs al-
lows for rapid alterations in gene expression in response to
fluctuations in iron concentrations, and ensures that cells acquire
sufficient iron for their needs while preventing iron toxicity.
Although IRP1 and IRP2 share 64% amino acid sequence
identity the regulation of their RNA binding activity occurs
through different mechanisms. Both IRPs are members of the
aconitase family of proteins [89,90]. IRP1 is a dual function
protein that exhibits twomutually exclusive activities depending
on cellular iron status. IRP1 binds the IREwith very high affinity
when cells are iron-deficient. When iron levels rise, a [4Fe–4S]
cluster is assembled in IRP1 resulting in the loss of high affinity
RNA binding capacity and the acquisition of aconitase activity.
In fact, in the iron-replete form, IRP1 is the cytosolic isoform of
aconitase (c-acon) [91–95]. Aconitases are ancient enzymes that
interconvert citrate to isocitrate through a stereospecific dehy-
dration/rehydration mechanism requiring direct binding of
substrate to the [4Fe–4S] cluster [96,97]. Formation and com-
plete loss of the [4Fe–4S] cluster is required for functionalIREs located in either the 5′- or 3′-UTRs of specific mRNAs. During low iron
s in Tf R mRNA, resulting in the translational repression of 5′ IRE-containing
se their affinity for IREs, increasing translation of 5′ IRE-containing mRNAs and
ion of the IRP1 RNA binding form into the [4Fe–4S] cluster c-acon form, while
the 3′ IRE in DMT1 mRNA is functional is not clear.
Fig. 3. Predicted structure of ferritin andm-acon IRE regions. (A) The rat L-ferritin
IRE plus flanking sequences (IRE region). Note that ferritin IRE is the central part
of a large stem loop structure stabilized by sequences flanking the IRE. This
structure has been confirmed in solution [143,150]. The 5′ and 3′ ends of the ferritin
28 nt IRE are indicated by arrows 1 and 2. The internal loop/bulge is indicated
(bracket 3) as is the terminal loop (bracket 4). Potential basepairing between loop
nucleotides 1 and 5 is shown. (B) m-acon 5′UTR structure using the best example
of an IRE-like fold obtained from computer predictions. In contrast to the ferritin
and Fpn IRE regions, the m-acon IRE is not predicted to form as frequently. The
highly conserved RNA sequence flanking [134] the m-acon IRE lacks extensive
basepairing since, in contrast to ferritin and Fpn, the m-acon (and eALAS) IRE is
b10 nt from the 5′ end. The 5′ CAP is shown for m-acon (★); ferritin cap is 28 nt
from 5′ end of IRE. Structures were predicted by M-fold version 3.2.
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through protein degradation [98,99]. One notable difference
between IRP1 and IRP2 is the presence of a unique 73-amino
acid (73-aa) insertion near the N-terminus of IRP2. Unlike IRP1,
IRP2 cannot form a [4Fe–4S] cluster, and hence does not exhibit
aconitase activity [100].
How do the IRPs recognize IREs? The recently solved struc-
ture of the c-acon form of IRP1 provides evidence supporting the
prediction that the IRE binds within a cleft present between
domains 1–3 and domain 4 [101–103]. Similar to mitochondrial
aconitase, the [4Fe–4S] cluster sits deep in the solvent accessible
cleft of c-acon, although the cleft is deeper in c-acon [102]. In the
absence of the [4Fe–4S] cluster, the cleft is predicted to open
allowing RNA recognition [101,103]. Both the [4Fe–4S] cluster
and the IRE influence the conformation of IRP1 [104–106].
Since the IRPs do not contain classical RNA recognition motifs,
understanding how they bind RNA remains a major unresolved
issue. Studies indicate that IRPs require a stem and loop structure
in which the latter usually has the sequence CAGUGXwhere the
sixth nucleotide (nt) is usually U or C [107] (Fig. 3). The stem, or
RNA helix, contains an unpaired or “bulged” C residue five
basepairs 5′ of the loop. In the case of the H- and L-ferritin IREs,
this bulge is part of larger internal loop/bulge region while all
other 5′ or 3′ IREs are predicted to contain a single C-bulge (Fig. 3)
[107,108]. The sequence of the IRE loop and the presence of
the bulge nucleotide region are critical for IRP binding.
Differences in structure and sequence of the IRE RNA helix
contribute to differential binding of IRPs to specific IREs (see
below).
2.5. Regulation of IRE-containing mRNAs by IRPs
While iron controls ferritin expression transcriptionally and
through changes in protein stability [109,110], regulation of
ferritin mRNA translation is generally viewed as the primary
means for controlling cellular iron storage capacity. The increase
in IRE RNA binding activity in iron-deficient cells concordant
with the reduction in ferritin synthesis [75,76] argued that IRPs
act as repressors of mRNA translation. This was confirmed using
cell-free translation systems [111]. Examination of the 5′UTR of
ferritin, as well as other IRE-containing mRNAs, revealed that in
most cases the IRE lies within approximately 70 nt of the 5′
methylated cap present at the 5′end of mRNAs, suggesting that
cap proximity is important for IRP action.When a functional IRE
was presentmore than 70 nt 3′ of the cap, IRP no longer repressed
mRNA translation [112,113]. These studies established the “po-
sition effect” requirement for IRP function. Further analysis re-
vealed that IRP1 binding to the ferritin IRE failed to block
interaction of the cap binding complex eIF4F to themRNA5′end
[114]. However, IRP1 did block the recruitment of the small
ribosomal subunit and associated factors to ferritin mRNA, a step
requiring interaction with mRNA-bound eIF4F. Future studies of
IRP-dependent translational regulation will likely focus on
understanding how some IRE-containing mRNAs largely
evade IRP action (e.g., eALAS and m-acon mRNAs) and on
the mechanism(s) underlying derepression of IRE-containing
mRNAs [115].Iron regulation of TfR1 expression is largely controlled
through changes in RNA degradation [77,116] although TfR1
gene transcription and possibly protein stability can serve
important roles [116–119]. Iron-dependent control of TfR1
mRNA stability depends on the presence of five IREs and a rapid
turnover determinant in the 3′UTR, which provides a site for an
endonuclease [78–80,120,121]. One unanswered question is
why multiple IREs are needed for regulation? Recent analysis of
the 3′ UTR of TfR1 mRNAwhen IRPs are bound indicates that
structural changes in the IRE helix occur in the context of the
five IREs. These structural changes facilitate IRP2 binding and
do not occur when TfR1 IREs are examined as isolated ele-
ments. Unlike IRP2, IRP1 binds well to single TfR1 IREs [122].
These studies show that alterations in the structure of the TfR1
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enhancing the stability of TfR1 mRNA. Further work on the
identification of the nuclease(s) involved in TfR1 mRNA de-
gradation and determining how this nuclease(s) functions in
relation to IRP binding is needed. A second TfR isoform has
been identified that binds serum TF and has a role in sensing
extracellular iron [123–125]. However, TfR2 is not controlled
by IRPs.
In addition to TfR1, DMT1, MRCKα and CDC14A mRNA
appear to contain an IRE or IRE-like structure in the 3′UTR. The
IRE-like structure in DMT1 mRNA binds IRPs in vitro [126].
However, the function of this putative IRE is unclear. While
DMT1 mRNA levels can be iron-regulated [37,38,127], in other
scenarios the IRE-like structure appears to be non-functional
[128–130]. Furthermore, multiple alternatively spliced forms of
DMT1 mRNA are observed [127]. However, not all contain the
IRE-like structure and some of the non-IRE containing variants
are iron-responsive [127,128]. Whether the IRE-like structure in
DMT1 mRNA is functional remains to be determined. The
putative IRE in MRCKα mRNA binds to IRP and MRCKα
mRNA half-life is iron-regulated [88]. Future studies should
determine if the putative IRE in MRCKα is required for iron
regulation of MRCKα mRNA degradation. The function of the
putative IRE in one splice variant of CDC14AmRNA remains to
be confirmed by direct analysis of the regulation of CDC14A
mRNA expression by IRPs.
2.6. Evidence of combinatorial control by IRPs
The presence of IREs in mRNAs encoding proteins involved
inmultiple aspects of ironmetabolism or tricarboxylic acid cycle
function argue that these mRNAs are not identically regulated by
IRPs. This suggests that the IRE-IRP system likely uses com-
binatorial regulation to control iron and energy metabolism
[107]. Combinatorial control provides a mechanism where the
outputs (e.g., translation rate of specific mRNAs) from a system
of interest can be varied over a wide range in response to the
same signal. Evidence of combinatorial control by IRPs
comes from studies demonstrating the hierarchical translational
regulation of IRE-containing mRNAs [107]. Several studies
have shown that ferritin mRNA is more potently regulated than
m-acon or eALAS mRNAs [131–139]. In animal and cell
culture studies, ferritin protein abundance and synthesis rate
vary over a 50-fold range while m-acon varies by only 2-fold in
response to the same change in iron availability [134,137]. These
studies suggest that the IRE region in ferritin mRNA evolved
to promote optimal translational regulation. A key question
arising from these studies is how do some mRNAs with 5′
IREs largely evade IRP-dependent regulation while others are
strongly repressed? The answer appears to lie, at least in part, in
RNA (i.e., IRE) target site diversity, and differences in the
individual structural requirements of IRP1 versus IRP2 for RNA
recognition.
The general proof-of-principle that IRP1 and IRP2 have
overlapping but not identical requirements for RNA recognition
comes from SELEX experiments where novel IREs were
identified that bound preferentially to either IRP1 or IRP2[140–142]. A similar stem–loop secondary structure in all IREs
is recognized by IRPs, however, sequence and structural dif-
ferences in the helix of naturally occurring IREs can alter IRP
binding [108,143,144]. As noted earlier, all natural IREs are
generally composed of∼28 nt forming a stem–loop usually with
the loop sequence CAGUGX where X is usually a U or C. Base
pairing between the first and fifth nt of the loop has been
observed in NMR studies of the IRE, and is essential for IRP1
binding [141,145–147]. Sequences that constitute the stem
region of the canonical 28 nt IRE, and regions flanking it, are
much better conserved for the same mRNA (N95%) compared
to the same region in IREs of other mRNAs (∼30–80%)
[107,148]. All IREs contain an unpaired or bulged C residue in
the stem five nucleotides from the 5′ terminus of the loop.
However, in the ferritin IRE, the unpaired C is part of a larger
internal loop, the so-called internal loop/bulge (IL/B) region
(Fig. 3) [108,143,149,150]. The size of bulged nucleotide or
internal loop regions affects linking of RNA helices and in-
fluences accessibility of the major groove to protein contacts
[151–155]. IRP2 prefers the ferritin type IL/B IRE while IRP1
binds either the single C bulge or the IL/B type IRE [108,156].
As noted above, the TfR1 IREs, though predicted to exhibit a
single C-bulge, appear to form a structure similar to the ferritin
IL/B when present in their native sequence context [122].
Sequences outside or flanking the canonical 28 nt IRE sequence
can also affect IRE function [150,157]. For example, the ferritin
IRE is typically flanked by sequences that extend the RNA helix
such that the IRE is a central part of a larger and more stable
structure compared to the m-acon or eALAS IREs (Fig. 3). The
evidence suggests that the flanking sequences are structurally
integrated with the IRE in ferritin mRNA facilitating high
affinity binding of IRP1 and IRP2 [150]. Mutations in the IRE
region, which are linked to several human diseases, can decrease
or increase binding of IRPs [158–161].
These studies indicate that IRP1 and IRP2 have different
requirements for high affinity RNA binding in vitro and provide
a potential mechanistic basis for the differential regulation of
IRE-containing mRNAs in vivo [108]. Further support for this
concept comes from studies of mRNAs containing non-natural
IRE sequences that show IRP1 and IRP2 can selectively control
the translation of mRNA in cells [162]. However, studies of
natural IRE-containing mRNAs suggest that the correlation
between in vitro binding of IRPs to specific IREs and mRNA
regulation by IRPs in vivo has not been fully elucidated. Of
particular note is the finding that loss of IRP2, but less so IRP1,
leads to dysregulation of ferritin, TfR1 and eALAS expression
in mice [163–165]. These studies suggest that during normal
physiological conditions IRP1 cannot fully compensate for
IRP2. These results, however, appear to stand in contrast with
studies of IRP binding to specific IREs where IRP1 was found to
bind all IREs as well as, or better than, IRP2 and the finding that
IRP2 prefers the ferritin IRE [108,166]. This apparent
discrepancy may involve tissue specific differences in the
abundance of each IRP or of individual IRE-containing mRNAs
and will hopefully be resolved in future studies. The use of
animal models will be key to understanding how IRE sequence
and structure affect IRP function and how the selective actions of
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organismal metabolism.
3. Recent advances concerning the regulation of IRP
function
In recent years significant progress has been made in defining
many aspects of IRP1 and IRP2 regulation and function. For
IRP1 these include determining: (a) the physiological processes
and some participants underlying the assembly and disassembly
of its Fe–S cluster; (b) the role of phosphorylation in controlling
the aconitase function and mechanism of iron-regulation of
RNA binding; and (c) the consequences of dysregulation of
IRP1 function either through loss of its expression or its unre-
gulated activation. Advancements concerning the function and
regulation of IRP2 include: (a) identifying additional iron- and
heme-mediated regulatory mechanisms for controlling RNA
binding; and (b) the dysregulation of iron metabolism and
neurodegenerative events that occur when IRP2 is ablated.
3.1. Linkages between IRP1 and pathways of Fe–S cluster
assembly
The presence of the [4Fe–4S] cluster in the c-acon form of
IRP1 has unique consequences for the regulation of IRP1 func-
tion. First, it provides a connection between the regulation of
cellular iron metabolism by IRP1 and a central pathway of iron
consumption, the assembly of Fe–S proteins. Second, the sol-
vent accessibility of the [4Fe–4S] cluster in aconitases renders
them sensitive to cluster perturbants including reactive oxygen
(superoxide anion, O2·−) and nitrogen species (nitric oxide, NO;
peroxynitrite, ONOO−) that promote disassembly of the cluster.
This makes IRP1 particularly responsive to oxidative or inflam-
matory stresses or to environmental agents (e.g., paraquat) that
are capable of inducing formation of specific cluster perturbants.
Third, the action of such perturbants can be controlled by
phosphorylation of IRP1/c-acon or by the presence of aconitase
substrates (e.g., citrate) or inhibitors [167,168] that can impair
perturbant action by binding the Fe–S cluster.
Studies in yeast have provided insight into the metabolic
relationships between pathways of iron metabolism and the
sensing and regulation of iron homeostasis [169–171]. These
studies indicate that the flux of iron through the mitochondrial
Fe–S assembly pathway, and not the absolute concentration of
cellular iron, serves as a key indicator of cellular iron status.
Changes in Fe–S cluster assembly are sensed by the critical
transcriptional regulators of yeast ironmetabolism,Aft1 andAft2
[171]. Analysis of the pathways of Fe–S cluster assembly in
mammalian cells lags behind what is known in yeast but recent
studies have begun to identify the mitochondrial and cytosolic
participants. Frataxin, a mitochondrial matrix protein defective in
Friedreich's ataxia (FA), has a role in the formation of mito-
chondrial and cytosolic Fe–S proteins but its precise function is
still being elucidated [60,62,172,173]. The mitochondrial ABC
half-transporter Abcb7 appears to be required for maturation of
cytosolic Fe–S proteins as is its yeast orthologue, Atm1p, and is
defective in X-linked sideroblastic anemia with ataxia (XLSA/A)[60,62,174]. Using a genetic approach in yeast, Walden and
colleagues [175] identified Cfd1 as a cytosolic factor that pro-
motes cluster assembly in IRP1. Cfd1 appears to be a P-loop type
ATPase required for cytosolic Fe–S cluster assembly. Lill and
coworkers have identified additional yeast cytosolic proteins that
likely function together with Cfd1 to form the so-called CIA, or
cytosolic iron–sulfur cluster assembly, machinery (reviewed in
[60]). Mammalian orthologues of these proteins exist, which
suggests that the CIA machinery may play a role in iron-sensing
by IRP1 in vivo. Recent identification of cytosolic members of
the iron sulfur cluster (Isc) assembly gene family in mammalian
cells suggest that multiple systems may promote Fe–S cluster
assembly or Fe–S cluster repair in the cytosol [62,176,177].
Recent evidence supports a role of mitochondria in the con-
version of IRP1 to c-acon [178–183] and are consistent with
results in yeast wherein this organelle has an essential role in
cytosolic Fe–S cluster assembly [60]. The recent studies in mam-
malian cells show that impairment of mitochondrial [178–183] and
cytosolic [177] Fe–S cluster assembly pathways leads to acti-
vation of IRP1 RNA binding activity and a decrease in cytosolic
aconitase activity. Disruption of these pathways of Fe–S bio-
genesis can result in maladaptive changes in ironmetabolism. For
instance, a mutant mitochondrial glutaredoxin involved in iron
sulfur cluster biogenesis was recently found to cause anemia in
zebrafish due to defects in IRP1, but not IRP2; over-activation of
IRP1 leads to excessive repression of eALAS and hence, heme
formation [183]. Studies of the etiology of the human diseases FA
and XLSA/A have provided further insight concerning the re-
lationships between Fe–S biogenesis and ironmetabolism.While
FA appears to primarily be a disease involving altered mito-
chondrial function, including Fe–S biogenesis, recent evidence
demonstrates that an inappropriate activation of IRP1 may con-
tribute to pathological changes in iron metabolism [181,182].
Furthermore, disruption ofAbcb7, also impacts IRP1.Abcb7, like
its yeast counterpart Atm1p [184], is proposed to transport mi-
tochondrially derived metabolites to the cytosol for cluster bio-
genesis. Loss of Abcb7 in liver results in a several-fold activation
of IRP1 RNA binding [180]. A smaller activation of IRP2 was
also observed. This response of IRPs is associated with increased
TfR1mRNAabundance and increased iron accumulation. Hence,
it appears that like yeast, cellular iron sensors in mammalian cells
respond not to the total level of iron but to the size of a regulatory
iron pool or perhaps to the flux of iron though specific pathways
(e.g., Fe–S assembly pathways). Furthermore, it is apparent that
there is significant interplay between mitochondrial and cytosolic
pathways of iron metabolism in eukaryotes from yeast to mam-
mals. Additional work is needed to further define the link between
cellular Fe–S biogenesis and the regulation of iron metabolism in
mammalian cells including how dysregulation of IRP1 contri-
butes to maladaptive changes in cellular iron metabolism in
human disease.
3.2. Pathways of Fe–S cluster disassembly affect IRP1 function
Much interest has focused on how the Fe–S cluster in c-acon
is disassembled in order to generate IRP1 RNA binding activity
(Fig. 4). This is important not only in response to oxidative or
Fig. 4. Pathways for regulation of IRP1: IRP1 can be regulated through mechanisms dependent or independent of the [4Fe–4S] cluster. In the cluster dependent
pathway IRP1 has dual roles either as a high affinity IRE RNA binding protein when devoid of the [4Fe–4S] cluster or it is the cytosolic isoform of aconitase (c-acon)
when the [4Fe–4S] cluster is assembled. The c-acon form does not bind RNAwith high affinity. The [4Fe–4S] cluster is accessible to lowmolecular cluster perturbants
including reactive oxygen species (ROS) such as O2·− and H2O2 or reactive nitrogen species such as NO· or ONOO−. Hypoxia stabilizes the c-acon form by reducing
the level of oxygen or ROS. IRP1 can be phosphorylated at S138 and S711; both sites are not accessible in the c-acon form but are readily phosphorylated in the RNA
binding form. Studies with phosphomimetic mutants of IRP1 indicate that the Fe–S cluster can be assembled and the protein exhibits robust aconitase activity.
However, the Fe–S cluster is much more sensitive to disruption by cluster perturbants including oxygen and hydrogen peroxide. Iron stimulates the degradation of
S138 phosphomimetic mutants of IRP1 as well as S138 phosphorylated IRP1. The non-phosphorylated IRP1 apoprotein is also subject to iron induced protein
degradation when the Fe–S cluster biogenesis pathway is impaired.
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of how IRP1 is activated merely in response to iron deficiency.
The Fe–S cluster of c-acon does not spontaneously disassemble
when iron levels are low, at least on a physiological time scale.
Instead, the disassembly process must be initiated by factors
extrinsic to c-acon. Several studies have examined the role of
cluster perturbants such as O2 and O2 metabolites as well as
reactive nitrogen species such as nitric oxide (NO) or peroxy-
nitrite (ONOO−) (Fig. 4) that will be discussed here. It is im-
portant to note, however, that protein-mediated removal of the
[4Fe–4S] cluster of c-acon has not been ruled out. Lowmolecular
weight cluster perturbants (e.g., O2·
−) promote loss of the Fe–S
cluster and increase RNA binding activity or in some cases
damage the IRP1 apoprotein leading to its inactivation (reviewed
in [10,185,186]). There are several situations where oxygen or
ROS likely influence the balance between c-acon and IRP1.
These include the constant presence of oxygen or ROS in cells
and the changes in their level in response to hypoxia or oxidative
stress such as during ischemia/reperfusion injury, in the action of
specialized cells (e.g., macrophages) [186–188] or in response to
certain drugs [185,189,190] or toxicants [191,192].
ROS can influence IRP1 function though multiple mechan-
isms and produce different responses depending on the amount
and species of ROS examined. IRP1 RNA binding activity can
be increased by oxygen and reactive oxygen species (ROS)
[179,193–197]. Interestingly, the level of oxygen or ROS
influence iron-regulation of IRP1 in animals and cultured cells
[179,194–196]. The reduction in IRP1 RNA binding activity in
response to hypoxia is antagonized by iron chelation [194],
suggesting that iron and cluster perturbants have opposing
effects on the interconversion of IRP1/c-acon [179,194,195]. In
contrast, reversal of the effect of hypoxia on IRP1 by re-oxygenation is dependent on new protein synthesis suggesting
inefficient conversion of c-acon to IRP1 or that cluster removal
is protein-mediated in some cases [194]. Recent evidence
demonstrates that the response of IRP1 to hypoxia and re-
oxygenation can vary in a cell type specific manner, depending
on whether cells use additional levels of gene regulation to
control ferritin expression [198]. IRP1 also can be inactivated
by high levels ROS. Under such circumstances IRP1 is
inactivated presumably through oxidative damage [190,192]
and/or degradation [179,197,199]. The loss of IRP1 in response
to high levels of ROS and other cluster perturbants may
represent a means to prevent over accumulation of RNA
binding activity. Cluster removal from c-acon is regulated by
the action of H2O2, rapidly activating IRP1 through a
membrane-initiated signaling pathway [188,196]. Direct treat-
ment of c-acon with H2O2 does not generate RNA binding
activity indicating that additional proteins, and/or altered
sensitivity of c-acon to cluster perturbants, must be involved
in IRP1 activation when intact cells are treated with H2O2 [200].
The action of H2O2 on IRP1/c-acon can be antagonized by other
oxidants in cultured cells [201]. Finally, it is of interest to note
that aconitases can vary in the stability of their Fe–S cluster
[202], and in the case of IRP1/c-acon the stability of the cluster
is regulated through phosphorylation of IRP1 at S138
[203,204]. S138 phosphomimetic mutants of c-acon display
enhanced sensitivity to oxygen and H2O2 [203,204]. Future
studies are needed to address issues including the mechanism
and efficiency of conversion of c-acon to IRP1 and the extent to
which dead-end inactive forms of the protein are produced in
response to oxidants [204]. Finally, additional animal models
are needed in order to more clearly establish the roles of ROS in
controlling IRP function and iron homeostasis in vivo.
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other reactive nitrogen species (RNS) such as peroxynitrite
(ONOO−) in influencing iron metabolism because the Fe–S
cluster of aconitases has long been known to be a target of these
agents [205]. Modulation of IRP function by RNS has been
suggested to have important roles in both the inflammatory
response and in aspects of cell-mediated immunity[185,206,
207]. Numerous studies using cultured cells and more impor-
tantly, purified IRP1/c-acon protein, have established that under
suitable conditions NO and ONOO− increase IRP1 RNA bin-
ding by directly targeting the Fe–S cluster, and in the case of
NO, promoting iron loss from cells [208–215]. Future studies
need to resolve a number of critical issues concerning the role of
RNS in controlling the function of IRP1. First, what are the
biologically relevant RNS that act on c-acon to convert it to
IRP1? Second, how do these reactive species modify c-acon and
what species of IRP1 are created?
It is now generally accepted that the Fe–S cluster of aconi-
tases is a direct target of NO [209,210,216–219]. This was
demonstrated by loss of aconitase activity, loss of cluster iron
and spectroscopic analysis. Together these results indicate that
NO directly attacks, and promotes complete removal of the Fe–S
cluster in aconitases with generation of high affinity RNA bin-
ding activity. NO treatment of c-acon can directly generate RNA
binding activity without a need for additional proteins or other
compounds (e.g., reductants) [219]. However, exposure to NO
also leads to the generation of other forms of IRP1 such as
dinitrosyl iron specie(s) or possibly S-nitroso-IRP1, that lack
aconitase activity [210,219,220]. Future studies should deter-
mine the efficiency of NO-mediated conversion of c-acon to the
RNA binding form or to other species. It will also be necessary to
determine whether NO-generated forms of IRP1 (e.g., the dini-
trosyl iron form of IRP1) are functional pools of the protein or
are degraded within the cell.
Because NO reacts very rapidly with superoxide anion to
produce the strong oxidant ONOO−, many investigations have
proposed that ONOO− elicits the biological response [208,216,
221–223]. In the case of c-acon, there are differing views con-
cerning the mechanism of action and efficacy of ONOO− in
enhancing accumulation of IRP1 RNA binding activity. The
commonality in these in vitro studies is the increased efficiency
of ONOO−, compared to NO, in inactivating c-acon [210,216,
219,220,222,223]. Critical unresolved issues are what are the
species of IRP1 produced after disruption of the Fe–S cluster by
ONOO−, are they observed in vivo, andwhat are their fate? These
species include the [3Fe–4S] form of c-acon [220], multiple
species of IRP1 with Cys residues in different oxidation states
[224,225], or tyrosine nitrated IRP1 [219,220]. Examination of
these issues is needed in order to establish the physiological
relevance of ONOO− in influencing c-acon/IRP1 function.
Exposure of c-acon to oxidants including ONOO− can lead
to loss of the Fe–S cluster and generation of an oxidized form of
IRP1 that does not bind RNA unless a reductant is added
[106,219,224]. However, in response to ONOO−, a significant
fraction of IRP1 appears to be permanently inactivated leading
to the conclusion that this oxidant disrupts the normal role of
IRP1 in controlling iron metabolism [106,219,220,224]. Incontrast, some studies suggest that exposure of c-acon to low
levels of ONOO− might activate RNA binding with higher
levels inactivating the RNA binding [216]. It is not clear how
ONOO− alone leads to production of the reduced apoprotein
form of IRP1 since it appears that no reductants were included
in the assays [216]. Future studies need to determine which
species of IRP1 protein are produced after exposure of purified
c-acon to ONOO− as well as how, and if, they can be converted
to the active RNA binding form. Furthermore, determining
which of these species of IRP1 are formed in cells and can be
converted to an RNA binding state or are degraded is another
important goal.
Translating these in vitro studies with purified c-acon or cell
lysates into an understanding of which RNS affect IRP1 in vivo
and which species are the most effective is a challenging task.
When considering the impact of ONOO− on cellular function one
must contend with its ability to react with a broader range of
compounds than NO, since NO is more restricted in the target
proteins it can react with (e.g., proteins containing transition
metals cofactors), the greater ability of NO relative to ONOO− to
cross cell membranes, and the fact that ONOO− has an extremely
short biological half-life [221]. Evidence suggesting a role of
ONOO− in influencing IRP1 in vivo comes from studies demon-
strating nitration of purified c-acon and the detection of nitrated
IRP1 in activated macrophages, although these findings in cell
culture could reflect the action of ONOO− on c-acon or the
apoprotein form of IRP1 [219,226]. Since ONOO−, but not NO,
promotes tyrosine nitration of proteins, these studies support the
idea that like NO, there is a role for ONOO− in vivo [221].
However, the efficient generation of IRP1 RNA binding activity
in cells by pharmacological and physiological agents that in-
crease NO production, coupled with the short half-life and
reduced specificity of ONOO−, suggest that NO may be the
primary RNS controlling IRP1 function. Taken together, impor-
tant future goals in this aspect of the IRP1 field includes deter-
mination of the species of IRP1 produced in cells in response to
RNS and increased focus on the physiological or pathological
circumstances under which these agents control ironmetabolism.
3.3. Phosphorylation dictates the mechanism of iron regulation
of IRP1
Both IRPs are regulated by phosphorylation [179,227] and
recent advances have beenmade in this area regarding IRP1. The
RNA binding and aconitase functions of IRP1 can be controlled
through protein kinase C (PKC)-dependent phosphorylation
[106,179,227–231]. Two PKC phosphorylation sites are present
in IRP1, S138 and S711 [179,229,231]. Genetic approaches
using S711 phosphomimetic mutants of IRP1 indicate that the
aconitase function is targeted selectively in that the forward
reaction (citrate to isocitrate) is severely inhibited while the
reverse reaction is much less affected [229,231]. Aconitases
operate in twomodes and it appears that phosphorylation at S711
impairs the citrate but not the isocitrate mode. S711 phospho-
mimetic mutants can retain high affinity IRE binding activity
although the protein appears to be unstable [229,231]. Further
studies are needed to determine how S711 phosphorylation
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binding activity in cells.
Recent evidence indicates that IRP1 can be iron-regulated by
Fe–S cluster-dependent or Fe–S cluster-independent means and
that S138 phosphorylation favors the latter. The classical model
for iron regulation of IRP1 involves control of RNA binding
activity by insertion or loss of the [4Fe–4S] cluster with no
change in total IRP1/c-acon protein level. However, it had been
known for years that IRP1 protein is degraded in response to high
levels of heme or genetic iron overload but the underlying
mechanism for this response was not clear [232–234]. The recent
finding that S138 phosphorylation provides a means to invoke
the protein degradation response begins to describe such a me-
chanism [179,230] (Fig. 4). S138 phosphomimetic mutants of
IRP1 display a so-called cluster instability phenotype in that they
can assemble a [4Fe–4S] cluster, and exhibit robust aconitase
activity, but the Fe–S cluster is markedlymore sensitive to cluster
perturbants [203,204]. A consequence of this phenotype is
increased accumulation of IRP1 in the RNAbinding form and the
suggestion that the Fe–S cluster might not be required for re-
gulation of RNA binding activity. Interestingly, the S138E phos-
phomimetic mutant undergoes iron-dependent protein degradation
[179,230] in a manner that does not require the [4Fe–4S] cluster
[179]. The fact that S138 phosphorylated IRP1 also undergoes
iron-dependent degradation argues that phosphorylation at this
residue invokes a cluster-independent means for regulating IRP1
[179]. Furthermore, a mutant of IRP1 that cannot be phosphory-
lated at S138, nor form the Fe–S cluster, was also subject to iron-
dependent degradation. This indicates that S138 phosphorylation
can promote, but is not required for, Fe–S cluster independent
regulation of IRP1. Further support for the cluster-independent
mechanism of IRP1 regulation came from studies of mice with
genetic defects in Fe–S cluster assembly or disassembly where,
unlike the situation in wildtype mice, liver IRP1 was primarily
regulated by protein degradation [179]. These studies indicate that a
secondmechanism is available to control the accumulation of IRP1
RNA binding activity that can serve as a safeguard when the
assembly or disassembly of Fe–S clusters is improperly regulated
(Fig. 4). Furthermore, given the different RNA binding character-
istics and kinetics of regulation of S138 phosphorylated IRP1 this
alternative mechanism for iron-regulation can be invoked to meet
the specialized iron needs of proliferating cells or during other
situations where the metabolic fate of iron is diverted to specialized
needs [179].
Taken together, progress in recent years has illustrated the
critical role of the [4Fe–4S] cluster in the regulation of IRP1
function in response to oxidative or inflammatory stresses but has
also revealed that IRP1 can be iron regulated in a manner not
requiring the [4Fe–4S] cluster. Clearly, multiple agents capable
of disrupting the Fe–S cluster in c-acon can promote accumu-
lation of IRP1 RNA binding activity. It is clear that cluster
perturbants act together with iron to control the distribution of
IRP1 between its RNA binding an aconitase forms. However, the
recent findings that high levels of IRP1RNA binding activity can
be deleterious to cell function [183] supports the concept that
multiple means are needed to control accumulation of IRE bin-
ding activity by IRP1. Iron-dependent regulation of the stabilityof IRP1 protein provides a mechanism to control accumulation of
IRE binding activity that does not require the [4Fe–4S] cluster
and which results in different kinetics and/or magnitude of res-
ponse of IRP1 to changes in iron status or to factors other than
iron (e.g., growth factors). Differences in the capacity of cells and
tissues to control the expression of IRP1 RNA binding activity
using the cluster-dependent or cluster-independent mecha-
nisms may be predictive of their response to various pathological
insults.
3.4. Functions for aconitases in lower organisms
In plants and some microorganisms, c-acon is involved in the
glyoxylate pathway, allowing these organisms to convert lipids
into glucose and other essential compounds. Although c-acon in
Caernorhabditis elegans shares striking resemblance to mam-
malian IRP1, it fails to bind RNA, which is consistent with the
lack of IREs in the C. elegans genome [235]. Other IRP1-related
proteins in organisms such as Arapidopsis thaliana, Nicotiana
tabacum and Trypanosome brucei were reported to possess aco-
nitase activity, but no RNA binding activity was reported for
these proteins [236–238]. Finally, recent work demonstrates that
of the two cytosolic aconitases in Drosophila, only one can bind
RNA [239]. This interesting finding supports the concept that
both the aconitase and RNA binding functions of IRP1 have
important roles in cell function.
The bifunctional roles of aconitases are not limited to animal
cells. Genetic and biochemical studies of bacterial aconitases
suggest that they can post-transcriptionally control aspects of
iron and energy metabolism arguing that the dual function of
this unique family of proteins has been exploited for some time
[84–86]. Perhaps most striking is the recent finding that mito-
chondrial aconitase has a major role in the maintenance of mi-
tochondrial DNA in yeast [240]. This function of yeast aconitase
does not require formation of the Fe–S cluster and appears to
involve association of the protein with mitochondrial DNA.
Hence, aconitases continue to surprise us with their unexpected
roles in cell function.
3.5. Mechanisms of IRP2 regulation
Although human IRP1 and IRP2 are 64% identical and 75%
conserved, several differences between the proteins are ap-
parent. The foremost structural variation is the presence of a
unique 73 amino acid (73-aa) region at the N-terminus of IRP2.
Even though IRP2 contains the conserved cysteines involved in
[4Fe–4S] cluster assembly, it cannot assemble a [4Fe–4S] clus-
ter [241] and fails to function as c-acon during iron-sufficient
conditions [100]. Instead, the decrease in IRP2 RNA binding
activity during iron-sufficient conditions is accompanied by a
reduction in protein levels [98–100,242].
The primary regulators of IRP2 protein abundance are iron
and oxygen. IRP2 protein levels are diminished during iron-
sufficient conditions [98–100,242] by a post-translational me-
chanism, since mRNA stability and protein synthesis are unaf-
fected by cellular iron status [98,194]. The iron-dependent
reduction of IRP2 protein levels is mediated by proteasomal
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labile protein(s) [243]. Unlike iron, hypoxia stabilizes IRP2
[244–247]. As cellular oxygen tension decreases from 21% to
3%, IRP2 protein levels andRNAbinding activity increase [195].
The hypoxic stabilization of IRP2 can be reversed by treatment
with iron [195,244] showing that IRP2 stabilization is not due to a
general decrease in proteasomal function during hypoxia. The
regulation of IRP2 by oxygen deserves significant consideration
due to the hypoxic nature of most tissues. At physiological
oxygen tensions, IRP2 is the predominant RNA binding protein
since IRP1 is mainly in its c-acon form [137,195], although this
can depend on iron status [137]. IRP2 may have evolved to
regulate IRE-containing mRNAs in vertebrates since it is
conserved in mammals, frogs, and fish and is absent in flies,
worms, and trypanosomes. The IRP2 binding preference for the
H- and L-ferritin IREs [108,156] supports this concept, since
translational regulation is the primary mechanism for ferritin
regulation in vertebrates.
Three models for iron-mediated IRP2 degradation have been
proposed (Fig. 5). For many years, the predominant model for
iron-dependent IRP2 degradation has involved the unique 73-aa
region of the protein. In this first model, three of the five cysteines
in the 73-aa region (C168, C174 and C178) facilitate an iron- and
oxygen-dependent oxidative modification that signals for protein
ubiquitination and ultimately proteasomal degradation [99,248].
In vitro studies with a 63-aa peptide, which corresponds to a
subset of the 73-aa region, indicate that these three cysteines
coordinate ferrous iron and that one cysteine is oxidatively
modified to dehydrocysteine and other products [249]. Removal
of the 73-aa region from IRP2 abolishes its iron-dependent
degradation in the human rhabdomyosarcoma RD4 cell line,
while insertion of the 73-aa sequence into IRP1 confers iron-
dependent degradation to IRP1 [99,250]. Taken together, this
work suggests that the 73-aa region of IRP2 is necessary for iron-Fig. 5. Proposed models for iron-dependent and iron-independent IRP2 regulation.
specific amino acid(s), which is then recognized by a specific E3-ubiquitin ligase
Alternatively, iron/oxygen activates a 2-OG-dioxygenase that hydroxylates IRP2, wh
degradation while NO· stabilizes IRP2. Hypoxia, iron chelators and the 2-OG-dioxy
degradation. IRP2 iron-independent pathway: phosphorylation regulates IRP2 RNA
phosphorylated form and a low-affinity dephosphorylated form, which are regulated
mediated degradation. IRP2 phosphorylation may allow IRP2 to alter iron-homeostas
structure with three domains (I–III) connected by a linker to domain IV.dependent degradation. More recent studies using human
embryonic kidney 293 (HEK293) and human H1299 lung cancer
cells show that an IRP2 mutant protein lacking the 73-aa region
and an IRP2 (C168S/C174S/C178S) triple mutant protein are
both degraded during iron-replete conditions [246,251,252]. The
reason for these conflicting data is uncertain. However, these data
show that the 73-aa region of IRP2 is not necessary for iron-
mediated degradation at least in HEK293 or H1299 cells. This
suggests that multiple cell type specific mechanisms may exist to
regulate iron-mediated IRP2 degradation.
A second model for IRP2 degradation involves heme-
mediated protein oxidation. IRP2 degradation can be stimulated
by the administration of exogenous heme [232,251,253], al-
though it is not clear whether exogenous heme is directly affec-
ting IRP2 protein levels or if it is providing a source of free iron
following liberation from the porphyrin ring. Evidence for a
direct heme effect includes oxygen-dependent in vitro binding of
heme to C168 and the subsequent oxygen-dependent oxidation
of C174 and C178 in the IRP2 63-aa peptide [250,254,255].
Other in vitro studies, however, show that heme binds to C201
and H204 located within the 73-aa region [250], but outside the
region corresponding to the 63-aa peptide used by Jeong et al.
[255]. These amino acids are found in the sequence C201PFH204,
which resembles a canonical heme regulatory motif found in
proteins regulated by heme [256,257]. It is proposed that redox
exchange between these ligands generates an oxidative modifi-
cation that targets IRP2 for degradation. InRD4 cells,mutation of
C201 and H204 attenuates heme-mediated IRP2 degradation but
does not completely abolish it, which suggests that other amino
acids are required to coordinate heme [250]. Mutation of the five
cysteines (C135, C168, C174, C178 and C201) in an IRP1
molecule containing the 73-aa region fails to completely block
heme-mediated degradation in RD4 cells [99,250], suggesting
that heme may mediate its effect on IRP2 degradation at aIron-dependent pathway: iron and/or heme transiently bind IRP2 modifying a
(HOIL-1) leading to IRP2 ubiquitination (UB) and proteasomal degradation.
ich provides a target site for a specific E3-ubiquitin ligase. NO+ stimulates IRP2
genase inhibitor DMOG also stabilize IRP2. Proteasome inhibitors block IRP2
binding activity independent of iron. IRP2 can switch between a high-affinity
by specific protein kinases and phosphatases. Both forms are substrates for iron-
is independent of cellular iron concentration. IRP2 is displayed based on m-acon
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IRP2 protein lacking the 73-aa region or IRP2 proteins contain-
ing C168S/C174S/C178S or C137A/C168A/C174A/C178A/
C201A substitutions undergo proteasomal degradation in
hemin-treated H1299 cells and HEK293 cells [251,252]. One
possible explanation for these results is that like iron-mediated
IRP2 degradation, heme-mediated degradation mechanisms may
be cell type specific. The evidence for a direct heme effect on
IRP2 protein levels is primarily based on heme binding to the 73-
aa region of IRP2 in vitro since in vivo studies have yielded
conflicting results. While this is still a plausible model, it is
important to note the promiscuous nature of heme binding to
proteins in vitro [258].
Other studies indicate that exogenous heme functions only as
an iron source, since iron chelation abrogates heme-mediated
IRP2 degradation [251]. Interestingly, inhibition of heme
synthesis with the 5-aminolevulinate dehydratase inhibitor suc-
cinylacetone reduces both iron-mediated IRP2 degradation
[232,250,253,254] and, to a lesser extent, heme-mediated IRP2
degradation [250,251]. This implies that iron mediates IRP2
degradation, at least partially, by stimulating heme synthesis, and
that exogenous heme may be degraded intracellularly or pro-
cessed differently from endogenous heme. Whether IRP2 senses
non-heme or heme iron, or both forms of iron, is unresolved.
Cellular heme content correlates with iron availability when iron
stores are limited [250]. During iron-sufficient conditions, how-
ever, IRP2 degradation occurs without an observed enhancement
of heme synthesis or cellular heme content [250]. Therefore,
multiple mechanisms involving both heme and iron sensing may
exist to regulate IRP2 during different cellular conditions.
Since the involvement of the 73-aa region of IRP2 in iron- and
heme-mediated degradation is controversial, the role of the re-
cently identified IRP2 E3 ubiquitin ligase HOIL-1 (heme-
oxidized IRP2 ubiquitin ligase-1) as the primary IRP2 E3 ligase
is unexpected. HOIL-1 was identified in a yeast two-hybrid
screen that utilized the oxidized recombinant 73-aa region of
IRP2 as bait [254]. HOIL-1 ubiquitinates heme- or iron-treated
IRP2 in vitro and binds to the 73-aa region of IRP2 in RD4 cells
treated with iron or heme, but not in cells treated with desferi-
oxamine [254]. These data show that the binding of HOIL-1 to
the 73-aa region is iron/heme dependent. HOIL-1 has been
previously identified in other yeast two-hybrid screens where it
interactedwith the hepatitis B virusX-protein [259], the E2 ligase
UbcM4/UbcH7 [260], the kinases PKCβI and PKCζ [261,262]
and the suppressor of cytokine signaling protein SOCS6 [263].
The role of HOIL-1 in ubiquitination and degradation of these
proteins has only been reported for SOCS6-associated proteins.
In some studies HOIL-1/RBCK1 was shown to act as a trans-
criptional activator that shuttled in and out of the nucleus [261,
262]. The interaction of HOIL-1 with many partners and the
dispensable nature of the 73-aa region of IRP2 for degradation in
some cell types suggest that another IRP2 E3 ubiquitin ligase
must exist.
A third model suggests that iron-mediated degradation of
IRP2 may involve the activity of a 2-oxoglutarate (2-OG)-de-
pendent dioxygenase, which requires iron, oxygen and 2-OG for
substrate hydroxylation [264]. Since both IRP2 degradation and2-OG-dependent dioxygenase activity are inhibited by desfer-
ioxamine, hypoxia and the hypoxia mimetic cobalt chloride, the
involvement of 2-OG-dependent dioxygenases in iron-mediated
IRP2 degradation was examined. DMOG, an inhibitor of 2-OG-
dependent dioxygenases, prevents iron-mediated IRP2 degrada-
tion [246,252]. DMOG does not appear to function as an iron
chelator since IRP1 RNA binding activity is not affected [246,
252]. This mechanism of IRP2 regulation may only be effective
when previously iron deficient cells are stimulated with iron,
since DMOG is less effective as an inhibitor of IRP2 degradation
in cells that do not receive pretreatment with desferioxamine
[252]. 2-OG-dependent dioxygenase activity may be required for
direct IRP2 hydroxylation but the identification of a hydroxyl-
ated site is required for definitive proof. It is also possible that
hydroxylation of an upstream component of the IRP2 degrada-
tion machinery is responsible for the stabilization of IRP2 by
DMOG.
Additional regulation of IRP2 is facilitated by nitric oxide
(NO). NO functions to stabilize or degrade IRP2 depending on
the type of NO donor used. Kim et al. show that sodium nitro-
prusside (SNP) treatment may induce S-nitrosylation at C178 in
the 73-aa region, which targets IRP2 for degradation in COS-1
cells [265]. Recent studies show that SNP-mediated IRP2
degradation may be due to the release of iron, not NO+, from
SNP. For example, IRP2 degradation can be blocked by
simultaneous treatment with SNP and desferioxamine
[251,266] and treatment of H1299 cells with photodegraded
SNP, which cannot release NO+, stimulates IRP2 degradation
[266]. These data show that SNP mediates its effect on IRP2
degradation by releasing the iron of nitroprusside leading to an
increase in intracellular iron levels [266]. S-nitrosylation of IRP2
may occur at C178 but it is unlikely that this modification
stimulates IRP2 degradation since an IRP2 protein lacking the
73-aa region or an IRP2 (C168S/C174S/C178S) mutant protein
both degrade in SNP- treated H1299 cells [266]. In contrast to the
stimulation of IRP2 degradation caused by the release of iron
from SNP, NO generated by the pharmacological NO donor S-
nitoso-N-acetyl-penicillamine (SNAP) or NO generated physio-
logically by B6.NOS cells stabilizes IRP2 [267]. IRP2
stabilization is apparently not due to a general decrease in
proteasomal function in response to NO and does not require the
73-aa domain [267]. The SNAP-generated NO may indirectly
regulate IRP2 by decreasing intracellular iron levels through the
formation of iron–nitrosyl complexes [268]. The mechanisms of
NO-mediated IRP2 regulation are not entirely elucidated.
Pharmacologically or biologically generated NO appears to
indirectly affect IRP2 stability by modulation of the intracellular
iron pool. Seemingly contradictory data may be a result of
technical or cell type specific differences.
IRP2 is also regulated by phosphorylation. Induction of HL-
60 cell differentiation by phorbol 12-myristate 13-acetate (PMA)
treatment stimulates IRP2 phosphorylation and increases RNA
binding activity [227]. Phosphorylation activates a latent pool of
IRP2, since the increase in RNA binding activity is not attribu-
table to an increase in IRP2 protein synthesis [227]. IRP2 phos-
phorylation provides a mechanism for converting IRP2 from a
low-affinity RNA binding form to a high-affinity RNA binding
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important for regulating TfR1 and ferritin during periods of
cellular proliferation, differentiation or stress.
Multiple mechanisms of IRP2 regulation may exist to
regulate iron homeostasis in different cell types or in response
to different cellular conditions. These mechanisms include the
iron- and/or heme-mediated regulation of IRP2 protein stability
and the iron-independent regulation of IRP2 RNA binding
activity by phosphorylation (Fig. 5). The exact manner by which
these regulators affect IRP2 protein stability and/or RNA
binding activity has yet to be determined. The 73-aa region of
IRP2 does not appear to be necessary for iron- and/or heme-
mediated degradation of IRP2 as previously thought. The use of
pharmacological agents like DMOG, SNP and SNAP has
yielded insight into the regulation of IRP2 by oxygen and nitric
oxide. However, these results should be interpreted carefully as
these agents may be indirectly modulating intracellular iron
levels. Future work will focus on the identification of iron- and/
or heme-mediated IRP2 protein modifications, IRP2 structural
changes or protein–protein interactions that modulate protein
stability and RNA binding activity. Additionally, expansion of
studies into animal models would provide a more physiological
setting to examine the complex regulation of IRP2.
3.6. Pathological effects of IRP1 and IRP2 deficiencies in mice
Genetically engineered mouse models of IRP1 and IRP2
deficiency have been generated. Mice with a targeted disruption
of the Irp1 gene display no overt phenotype [165,269] except for
mild dysregulation of ferritin expression in kidney and brown fat
[165]. The lack of an overt phenotype in Irp1−/− mice is sur-
prising given the conservation of c-acon in diverse organisms.
The physiological function of c-acon still remains elusive. These
data suggest that the c-acon and RNA binding forms of IRP1 are
dispensable, at least during normal physiology.
Mouse models of IRP2 deficiency have been generated by
constitutive and conditional inactivation of the Irp2 gene. Mice
homozygous for mutant Irp2 alleles were generated by the in-
sertion of a PGK-neomycin gene into exon 3/4 of the Irp2 gene
[29]. These mice developed mild microcytic anemia, erythro-
poietic protoporphyria and a progressive neurodegenerative di-
sease characterized by an unsteady wide-based gait, ataxia,
vestibular dysfunction, bradykinesia, tremors and postural de-
fects that develop after 6 months of age [29,163,270]. In these
mice, iron accumulates in liver, where it is associated with ele-
vated ferritin and reduced TfR1 expression, and in duodenum
where it is associated with elevated ferritin andDMT1 expression
[29]. In bone marrow, low iron stores and increased protopor-
phyrin IX and zinc protoporphyrin levels correlate with reduced
TfR1 expression and increased eALAS biosynthesis [163,164].
The microcytic anemia can be explained by translational
derepression of eALAS-IRE mRNA and the destabilization of
TfR1-IRE mRNA due to IRP2 deficiency. While many tissues
acquire iron by TF-dependent as well as TF-independent path-
ways, precursor erythroid cells are dependent mainly on TF-
bound iron for heme synthesis [271,272], and consequently,
IRP2 deficiency leads to reduced TfR1 expression and reducediron acquisition. Interestingly, a genetic approach in zebrafish
indicates that over-expression of IRP1 RNA binding activity can
also produce a microcytic anemia, due in this case to excessive
repression of eALAS mRNA translation [183].
Inactivation of both Irp1 and Irp2 (Irp2−/−Irp1−/−) genes
results in embryonic lethality at the blastocyst stage
[164,165,273]. Mice that lack both copies of IRP2 and one
copy of IRP1 (Irp2−/−Irp1+/−) develop more severe neurode-
generative disease at an earlier age than Irp2−/− mice [274]. The
neurodegeneration is characterized bywidespread axonpathy and
vacuolization in several regions of brain, notably the substantia
nigra. Irp2−/−Irp1+/− mice also show marked alterations in ferri-
tin and TfR1 expression in forebrain, develop microcytic anemia
and display abnormal iron homeostasis in liver. These studies
show that IRP2 functionally substitutes for IRP1, but that IRP1
only partially substitutes for IRP2.
The molecular basis for the neurodegenerative disease in
Irp2−/− and Irp2−/−Irp1+/− mice is not clear. However, dysre-
gulation of iron homeostasis is associated with neurodegenera-
tive diseases including Alzheimer's disease, Friedreich's ataxia,
Parkinson's disease and Pantothenate Kinase deficiency
[30,275]. In Irp2−/− and Irp2−/−Irp1+/− mice, ferritin and ferric
iron are elevated in neurons located in multiple regions of the
brain, including substantia nigra, hippocampus, caudate putamen
and cerebellum, and this correlates with axonal degeneration
[29,274]. TfR1 expression decreases in cerebellum and forebrain
extracts [29,165]. It is also possible that other IRE mRNAs, as
well as other genes, are dysregulated in brains from Irp2−/− and
Irp2−/−Irp1+/− mice, and that this dysregulation contributes to
axonal degeneration. Electron tomography shows that ferritin in
Irp2−/−Irp1+/− mouse brains is located in doubled-wall vesicular
compartments that are thought to be invaginations of oliogoden-
drocyte membranes into axons, while ferritin content in axons is
reduced [276]. The mechanism responsible for the reduced
axonal ferritin and axonal degeneration is not clear. Reduced
ferritin content in axons, however, may be associated with iron
deficiency, which ultimately could affect neuronal integrity. The
importance of ferritin in brain ironmetabolism ismade evident by
other studies showing that patients carrying a mutation in the
ferritin-L mRNA, which alters ferritin structure and function,
develop dominant adult-onset basal ganglia disease [28], while
Fth+/− mice display evidence of oxidative stress and iron
deficiency in brain [31].
A second model of IRP2 deficiency was generated by the
conditional inactivation of the Irp2 gene [164,269]. A β-gala-
ctosidase-neomycin (β-Geo) cassette flanked by Frt sites was
inserted into intron 2 of the Irp2 gene, disrupting the Irp2 open
reading frame and generating a null allele. The β-Geo was
inserted with LoxP sites flanking exon 3 to allow excision of
exon 3 by Cre recombinase to generate complete null alleles
lacking the β-Geo cassette. Like the Irp2−/− mice generated by
LaVaute et al. [29], Irp2−/− mice carrying the β-Geo cassette or
mice lacking this cassette develop microcytosis, with reduced
TfR1 mRNA expression in bone marrow and accumulation of
iron and ferritin in duodenum and liver [164]. Non-heme iron is
reduced in spleen and correlates with reduced ferritin and FPN
expression. Unlike LaVaute's Irp2−/− mice, FPN and DMT1
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old mice did not display the severe neurodegenerative disease
that was observed in the same age mice generated by LaVaute
et. al. [29]. The reason for the strikingly different neuro-
degenerative phenotypes between the two Irp2−/− mouse
strains is not clear. It is known, however, that different gene
targeting approaches can lead to different phenotypes. This
could be due to silencing of neighboring genes caused by the
generation of truncated gene products with biological activity
or the retention of selection cassettes [277]. A relevant example
of the latter case is the Irp1−/− mouse carrying the β-Geo
cassette, in which the presence of the cassette causes partially
penetrant embryonic lethality unrelated to IRP1 deficiency,
while its removal results in Irp1−/− mice born in Mendelian
ratios [269]. Another relevant example is the iron-loaded
phenotype of Usf2−/− (Upstream Stimulatory Factor 2) null
mice [278]. This phenotype was not due to Usf2 deficiency, but
rather to the silencing of adjacent hepcidin genes, since a
distinct Usf2−/− mouse generated by a different targeting
strategy was not iron-loaded [279,280]. The phenotype of
mutant mice can also be influenced by their genetic background
[281,282]. For example, natural variation in iron metabolism in
inbred mouse strains has been reported [283,284], which has
been shown to affect the severity of iron accumulation inHfe−/−
mice [285]. Whether the different neurodegenerative pheno-
types displayed by the two independent Irp2−/− mouse strains
are caused by different targeting strategies or are attributable to
their genetic background remains to be determined.
Why is IRP1 unable to fully compensate for the loss of IRP2
function in these models? A clue comes from studies showing
that the RNA binding activity of IRP1, but not IRP2, appears
refractory to activation in tissues of some, but not all [179],
strains of mice fed a low iron diet [165]. These studies suggest
that IRP1 is less sensitive to iron depletion in vivo, suggesting
that IRP2 could be the predominant iron sensor in mammalian
cells. One possible explanation for the reduced sensitivity of
IRP1RNAbinding activity to iron depletion is that in the hypoxic
environment of most tissues, IRP1 exists predominately in its
c-acon [4Fe–4S] cluster form [137,165,195,286]. The notion is
that the [4Fe–4S] cluster of IRP1 is stable in a low oxygen
environment, where free radical generation is expected to be low,
rendering IRP1 less sensitive to changes in iron concentration.
Other studies show that both IRP1 and IRP2 RNA binding
activities are activated in liver lysates isolated from rats and mice
fed a low iron diet, though RNA binding activity of IRP2 is
somewhat more sensitive to iron depletion than that of IRP1 in
rats [137,179,287,288]. IRP1 still has an important role in iron
homeostasis, based on the more severe neurodegenerative phe-
notype in Irp1+/−/Irp2−/− mice and the fact that Irp1−/−/Irp2−/−
mice are not viable past the blastocyst stage [164,274]. As men-
tioned earlier, recent work in zebrafish also indicates that over-
activation of IRP1 can have severe pathological consequences
[183].
Different tissue-specific expression patterns of IRP1 and IRP2
could also contribute to the distinct phenotypes of Irp1−/− and
Irp2−/− mice [122,243]. IRP2 shows the highest expression in
brain, skeletal muscle and heart, while IRP1 predominates inkidney, brown fat and liver. IRP1 and IRP2 also show distinct
expression patterns in mouse brain with respect to cell types
when analyzed by immunohistochemistry [289]. The fact that
IRP1 expression is highest in kidney and brown fat is consistent
with dysregulation of ferritin synthesis in these tissues in Irp1−/−
mice [165].
Another factor that might contribute to the distinct phenotypes
of Irp1−/− and Irp2−/−mice is the apparently difference in binding
affinities of IRP1 and IRP2 to IRE-mRNAs. This is due, at least
in part, to structural differences in the stem of the hairpin loop of
the IRE, which contains either a C-bulge (m-aconitase, eALAS or
TfR1) or an IL/B (ferritin) [108,145,147,290–292]. While the
ferritin-H IRE and the five TfR1 IREs bind IRP1 and IRP2 with
similar apparent affinities, m-acon, eALAS and single TfR IREs
may preferentially bind IRP1 [100,108,122]. Collectively, these
studies suggest that different mechanisms of regulation, expres-
sion patterns and RNA binding affinities of IRP1 and IRP2 con-
tribute to IRE-mRNA regulation.
3.7. Consequences of dysregulation of IRE-containing mRNAs
In addition to dysregulation of IRE-containing mRNAs due to
IRP1 and/or IRP2 deficiencies in mice, mutations in IREs or in
the coding or regulatory sequences of IRE genes can be dele-
terious. Targeted disruptions of the ferritin-H gene or of the TfR1
gene in mice result in embryonic lethality [31,293,294]. In
humans, mutations in the ferritin-L IRE cause hyperferritinemia
cataract syndrome [158,295–297], while a mutation in the
ferritin-H IRE, which increases IRP binding, is associated with
high serum ferritin levels and iron overload [159]. In a poly-
cythaemia (Pcm) mouse strain, a 58-bp deletion in the FPN
promoter results in aberrant transcriptional initiation and the
elimination of the 5′ IRE sequence in FPNmRNA, leading to the
accumulation of FPN protein in liver and gut [298]. This sug-
gests that the loss of the IRE may be responsible for altered FPN
expression. Missense mutations in the Fpn gene in humans cause
hemochromatosis type IV also known as autosomal dominant
ferroportin disease [299]. In one hemochromatosis patient, a
novel mutation in the Fpn gene was identified in the 5′ UTR
downstream of the IRE.Whether this mutation alters IRP binding
to the IRE has not been yet defined [161]. Finally, mutations in
the eALAS gene cause X-linked sideroblastic anemia [174].
These studies show that improper expression of proteins encoded
by IRE-containing mRNAs disrupt iron metabolism at the cellu-
lar and organismal levels, leading to neurodegenerative diseases,
iron overload and other diseases in humans, and lethality in
animal models.
4. Outlook
Future research in the IRP field will focus on elucidating the
multiple mechanisms responsible for the regulation of IRP1 and
IRP2, the consequences of loss or over-expression of each IRP
on cellular and organismal iron homeostasis, determining how
each IRP selectively regulates the use of specific target mRNAs
and identifying novel IRE-containing mRNAs. Further analysis
of the relationship between Fe–S assembly and disassembly and
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determination of the specific Fe-S assembly factors involved in
converting IRP1 to c-acon. The pathways used and species
produced during disassembly of the Fe-S cluster in c-acon in
response to cluster perturbants also needs further attention in
order to fully understand the mechanism of the Fe-S switch.
Additional mouse models for determining how disruption of
Fe–S cluster assembly or disassembly affects IRP1 and iron
metabolism are needed. Furthermore, determining how IRP1 is
controlled through phosphorylation and its role in cluster-
independent regulation is needed. Finally, a better understand-
ing of the tissue-specific mechanisms underlying the adaptive
responses to iron deficiency and the role of IRPs in this process
should shed light on the metabolic remodeling that likely occurs
in response to variations in iron availability. For IRP2, it will be
important to identify iron and/or heme induced protein
modifications and to determine whether multiple mechanisms
exist to regulate IRP2 protein stability in different cell types.
The mechanisms by which other effectors such as NO,
phosphorylation and DMOG affect IRP2 activity requires
further study. Additional mouse models of IRP2 deficiency
are needed to definitively determine if IRP2 deficiency causes
neurodegenerative disease, and if so, how dysregulation of
iron homeostasis in brain contributes to neurodegenerative
disorders.
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